University of Pennsylvania
This is an early phase study in patients with Tuberculosis (TB) to evaluate Fibroblast Activating Protein (FAP) activation as a marker of fibrosis. The Investigators propose to use FAP PET/CT to define the extent and location of FAP signals in lungs of TB patients early in TB treatment and after TB cure. These timepoints are chosen as they could be utilized to deliver treatments designed to prevent, predict, or treat Post-transplant Lymphoproliferative Disorder (PTLD). The overarching hypothesis is that greater FAP signals in lungs of adult TB patients are associated with greater imaging manifestations of PTLD after cure.
Most participants will be receiving care at the clinical practices of the University of Pennsylvania or through City of Philadelphia TB Control Program (named the Flick clinic). Patients may participate in this study if they are at least 21 years of age and will be approached about study participation regardless of race or ethnic background. The study anticipates enrolling up to 10 participants who meet eligibility requirements for this study. Accrual is estimated to occur over approximately 2 years. Investigators propose to use Fibroblast Activating Protein (FAP) PET/computed tomography (CT)…
Inclusion Criteria 1. Participants will be ≥ 21 years of age 2. Diagnosed with microbiologically confirmed (culture or Xpert MTB/RIF PCR positive on at least one respiratory sample) pTB 3. Be currently on or able to initiate standard drug-sensitive pTB treatment according to IDSA guidelines. 4. Have initiated or planning to initiate TB treatment prior to screening and enrollment. 5. Have a Timika CXR score indicating cavitary disease 6. Be able and willing to provide written informed consent to participate in the study Exclusion Criteria 1. Diagnosed with TB that is resistant to rifampin pe…
Each patient will receive approximately 8 mCi of \[18F\]-FAPI-74 intravenously (approximate range for most studies is anticipated to be 6-8 mCi). This will be followed by a vertex to thigh static scan at 30 minutes ( ±5 min) post injection and a low dose CT for attenuation correction. Participants will also undergo high-resolution CT (HRCT) of the chest at baseline and follow-up timepoints, these scans may be done the same day or on different days.
Arctuva estimate
Verify or correct the compensation shown for this listing.